Even with Medicare support, Omidria sales performance is not encouraging.
If approved, the lead candidate can face competition in a crowded market.
Absence of a commercial partner brings the risk of dilution.
Omeros Corporation (NASDAQ:OMER) is commercial stage pharmaceutical company with one marketed drug – Omidria, one late-stage, and several early-stage drug candidates.
Omidria is used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
Omidria is phenylephrine and ketorolac intraocular solution (1%/0.3%), and it was approved by FDA in 2014.
Actually, it is a combination of 2 previously available medicines: mydriatic phenylephrine and nonsteroidal anti-inflammatory drug ketorolac.
Despite the promising projections and Medicare coverage, the company still has not achieved a serious sales volume. In this terms, the question at the recent earnings conference, regarding the current market penetration of Omidria was indicative: